Abstract

A selected set of substituted pyridone-annelated isoindigos 3a–f has been synthesized via interaction of 5- and 6-substituted oxindoles 2a–f with 6-ethyl-1,2,9-trioxopyrrolo[3,2-f]quinoline-8-carboxylic acid (1) in acetic acid at reflux. Among these isoindigos, the 5'-chloro and 5'-bromo derivatives 3b and 3d show strong and selective antiproliferative activities against a panel of human hematological and solid tumor cell-lines, but not against noncancerous cells, suggesting their potential use as anticancer agents. In all the tested cell lines, compound 3b was a 25%–50% more potent inhibitor of cell growth than 3d, suggesting the critical role of the substitution at 5'-position of the benzo-ring E. The IC50 values after 48 hours incubation with the 5'-chloro compound 3b were 6.60 µM in K562, 8.21 µM in THP-1, 8.97 µM in HepG2, 11.94 µM in MCF-7 and 14.59 µM in Caco-2 cancer cells, while the IC50 values in noncancerous HEK-293 and L-929 were 30.65 µM and 40.40 µM, respectively. In addition, compound 3b induced higher levels apoptosis in K562 cells than 3d, as determined by annexin V/7-AAD flowcytometry analysis. Therefore, further characterization of the antitproliferative mechanisms of compounds 3b and 3d may provide a novel chemotherapeutic agents.

Highlights

  • Leukemia is one of the most fatal hematological cancers worldwide

  • We show that two of our synthesized compounds having a chlorine and bromine substitution at the 5'-position of the benzo-ring E, effectively inhibit proliferation of K562 cells in a dose- and time-dependent fashion with IC50 values ranging from 4 to

  • The mass spectra displayed the correct molecular ion peaks for which the measured high-resolution mass spectral (HRMS) data were in good agreement with the calculated values

Read more

Summary

Introduction

Leukemia is one of the most fatal hematological cancers worldwide. Human chronic myelocytic leukemia (CML), a highly common type of leukemia, is a myeloproliferative disorder of blood cells that is characterized by increased proliferation of undifferentiated granulocytic progenitors. CML is induced by constitutive expression and activation of the fusion gene Bcr-Abl encoding a tyrosine kinase, which develops from a translocation between chromosomes 9 and 22 to generate Philadelphia chromosome [1]. Imatinib mesylate (Glivec®), a specific inhibitor of Bcr-Abl activity, was developed as the first anticancer molecule to treat CML patients. A high percentage of CML patients were reported to develop resistance to Glivec® as a result of increased mutation incidents in the Abl kinase domain, indicating the requirement for new treatment regimen [1,2]. In the course of our laboratory studies aiming to synthesize compounds with potential antiproliferative activities towards leukemia cells, we have initiated a chemical synthesis program of indigoid derivatives. Indigoids are a class of bis-indole alkaloids, obtained from Baphicacanthus cusia (Nees) Bremek. (Acanthaceae), Indigofera suffruticosa Mill. (Fabaceae), Indigofera tinctoria L

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call